Cis-dichlorodiammineplatinum (II), VP 16-213, and prednisone (DVP regimen) in the treatment of pretreated advanced malignant lymphomas.

Abstract

Eighteen evaluable patients with advanced malignant lymphoma were treated with a combination of cis-dichlorodiammineplatinum (II) (50 mg/m2 i.v. on day 1), VP 16-213 (100 mg/m2 i.v. on days 1, 3, 5), and prednisone (50 mg/m2 per os on days 1-5), recycling every 2 weeks. All patients were previously pretreated. There were 3 complete remissions (patients with Hodgkin's disease), and 4 partial remission (2 patients with Hodgkin's and 2 with non-Hodgkin's lymphoma), for a median duration of 8 weeks. In addition, 2 minor responses (patients with Hodgkin's disease) were observed. Vomiting and myelosuppression were the most prominent toxic effects. In most heavily pretreated patients, myelosuppression was moderate to severe: in these patients and in patients with bone marrow involvement, a schedule interval of 3 weeks should be more appropriate. Nephrotoxicity was minimal. This combination chemotherapy showed some activity in the management of advanced malignant lymphomas; further studies in this area are justified.

• Authors: V P Fosser, L Salvagno, R Segati, G L Pappagallo, E Ferrazzi, V C Sileni, M V Fiorentino
• Journal: Tumori (Tumori) Vol. 68 Issue 6 Pg. 515-8 (Dec 31 1982) ISSN: 0300-8916 [Print] United States
• PMID: 6762740 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Etoposide
• Podophyllotoxin
• Cisplatin
• Prednisone

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols
• Cisplatin (administration & dosage, adverse effects)
• Clinical Trials as Topic
• Drug Therapy, Combination
• Etoposide (administration & dosage, adverse effects)
• Female
• Humans
• Lymphoma (drug therapy)
• Male
• Middle Aged
• Neoplasm Staging
• Podophyllotoxin (analogs & derivatives)
• Prednisone (administration & dosage, adverse effects)